The effect of antidementia drugs on mortality in patients with Alzheimer's disease

被引:2
|
作者
Lin, Wei-Hao [1 ,2 ]
Lin, Ching-Herng [3 ]
Hou, Po-Hsun [1 ,2 ,4 ]
Lan, Tsuo-Hung [1 ,2 ,5 ]
机构
[1] Taichung Vet Gen Hosp, Dept Psychiat, 450,Sec 1,Dongda Rd, Taichung 407, Taiwan
[2] Natl Yang Ming Univ, Dept Psychiat, Taipei, Taiwan
[3] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan
[4] Providence Univ, Dept Social Work & Child Welf, Taichung, Taiwan
[5] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Zhunan, Taiwan
关键词
Alzheimer's disease; antidementia drug; cholinesterase inhibitor; memantine; mortality; CHOLINESTERASE-INHIBITORS; RISK-FACTORS; DEMENTIA; DONEPEZIL; MEMANTINE; PATTERNS;
D O I
10.1177/0269881119845795
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Alzheimer's disease is associated with a higher mortality rate after the diagnosis. We hypothesized that patients with Alzheimer's disease who received antidementia drugs may have a lower mortality rate than those without such treatment. Methods: Patients with newly diagnosed Alzheimer's disease aged > 65 years during 2001-2006 were identified in the National Health Institute Research Database, Taiwan. We included patients with Alzheimer's disease who received antidementia drugs as the exposure group (ADD group), and compared them with a non-exposure group who did not receive any antidementia drugs (non-ADD group) matched for age at the index date, gender and Charlson Comorbidity Index score before the index date. All-cause mortality rates and Charlson Comorbidity Index scores at one and two years after the index date were compared between the ADD and non-ADD groups. Results: There were 529 patients in non-ADD group and 529 in the ADD group. The mortality rate was significantly lower in the ADD group compared with the non-ADD group (42% versus 58.6%; p<0.0001). Conclusion: Our results suggest that antidementia drugs may have a protective effect against mortality in patients with Alzheimer's disease.
引用
收藏
页码:986 / 993
页数:8
相关论文
共 50 条
  • [1] Use of antidementia drugs in German patients with Alzheimer's disease
    Hessmann, Philipp
    Dodel, Richard
    Baum, Erika
    Mueller, Matthias J.
    Paschke, Greta
    Kis, Bernhard
    Zeidler, Jan
    Klora, Mike
    Reese, Jens-Peter
    Balzer-Geldsetzer, Monika
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (02) : 103 - 110
  • [2] Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity
    Fukui, Yusuke
    Hishikawa, Nozomi
    Ichinose, Jin
    Sato, Kota
    Nakano, Yumiko
    Morihara, Ryuta
    Ohta, Yasuyuki
    Yamashita, Toru
    Abe, Koji
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2017, 17 (11) : 1991 - 1999
  • [3] Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017
    Yu, Lingyan
    Chen, Xueying
    Yu, Zhenwei
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (06) : 312 - 316
  • [4] Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
    Rountree, Susan D.
    Atri, Alireza
    Lopez, Oscar L.
    Doody, Rachelle S.
    ALZHEIMERS & DEMENTIA, 2013, 9 (03) : 338 - 345
  • [5] Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease
    Lampela, Pasi
    Tolppanen, Anna-Maija
    Tanskanen, Antti
    Tiihonen, Jari
    Lavikainen, Piia
    Hartikainen, Sirpa
    Taipale, Heidi
    ANNALS OF MEDICINE, 2017, 49 (03) : 230 - 239
  • [6] Long-term progression of Alzheimer's disease in patients under antidementia drugs
    Gillette-Guyonnet, Sophie
    Andrieu, Sandrine
    Nourhashemi, Fati
    Gardette, Virginie
    Coley, Nicola
    Cantet, Christelle
    Gauthier, Serge
    Ousset, Pierre-Jean
    Vellas, Bruno
    ALZHEIMERS & DEMENTIA, 2011, 7 (06) : 579 - 592
  • [7] Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment
    Pilotto, Alberto
    Polidori, Maria Cristina
    Veronese, Nicola
    Panza, Francesco
    Giancristofaro, Rosa Arboretti
    Pilotto, Andrea
    Daragjati, Julia
    Carrozzo, Eleonora
    Prete, Camilla
    Gallina, Pietro
    Padovani, Alessandro
    Maggi, Stefania
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (02) : 162 - 168
  • [8] The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease
    Kazmierski, Jakub
    Messini-Zachou, Chaido
    Gkioka, Mara
    Tsolaki, Magda
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2018, 33 (06): : 385 - 393
  • [9] Use of specific drugs for Alzheimer's disease
    Fernandez, I. Villar
    Hernandez, M. J. Rabaneque
    Gomez, J. Armesto
    Arilla, E. Garcia
    Rami, M. Lzuel
    NEUROLOGIA, 2007, 22 (05): : 275 - 284
  • [10] Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
    Moellers, T.
    Perna, L.
    Stocker, H.
    Ihle, P.
    Schubert, I.
    Schoettker, B.
    Froelich, L.
    Bauer, J.
    Brenner, H.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2020, 29 : 1 - 9